Sanofi Q1 profit slips on generic competition, forex effects
Nestle India profit beats estimates on strong demand; forms JV with Dr. Reddy's
Nestlé Health Science plots next steps for C. diff drug Vowst after robust uptake
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that the Company has received a $125 million milestone payment from Nestlé Health Science related to the U.S. Food and Drug Administration approval of VOWST™ (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibiotic treatment for recurrent CDI.
It seems Nestlé is experiencing some buyer’s remorse two years after throwing down $2.6 billion for Aimmune Therapeutics and its peanut allergy pill Palforzia.
Enterome, a clinical stage biopharmaceutical company developing immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, has signed a strategic R&D collaboration and license agreement with Nestlé Health Science targeting food allergies and inflammatory bowel disease (IBD).
For a fleeting moment, Nestle SA explored what would have been its biggest-ever deal in a move that underscores the consumer giant’s ambition to grow through large acquisitions. The Swiss company floated the idea in recent months of acquiring GSK Plc’s consumer health arm, people with knowledge of the matter said. It made informal overtures to express interest in the GSK unit around the same time as Unilever Plc’s £50 billion (US$63 billion) bid for the business that failed in January, the people said.
May 25 (Reuters) - The U.S. Department of Agriculture will temporarily cover the cost of baby formula for low-income families dependent on government discounts in states contracted with formula makers Nestle SA (NESN.S) and Reckitt Benckiser Group's Mead Johnson, the agency said Wednesday.
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- The nonprofit Mission: Cure, with the support of Aimmune Therapeutics, Inc., a Nestlé Health Science Company, has launched a new patient online community on the HealthUnlocked network, which will provide valuable support and information to people living with pancreatitis, helping them to live healthier lives. The online community is a much-needed space for patients who are suffering from this debilitating and isolating disease to connect and share their journey with pancreatitis in a supportive environment. Patients can join the community by following this link: https://healthunlocked.com/pancreatitis-support